Key Data Updates and Treatment Trends in Ovarian Cancer From ASCO 2025 - Episode 1

Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management

,

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss how ADCs could continue to reshape ovarian cancer management.

Now Viewing
EP. 1: Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management
EP. 2: Data for First-Line Dostarlimab and Niraparib in Advanced Ovarian Cancer: The FIRST Trial
EP. 3: TRUST Trial: Outcomes With Radical Up-Front Surgery in Advanced Ovarian Cancer
EP. 4: Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: The ROSELLA Trial
EP. 5: Findings for Neoadjuvant IMNN-001 Plus Chemo in Newly Diagnosed, Advanced Epithelial Ovarian Cancer
EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025 and Beyond